Edwards Financial Statements From 2010 to 2024

EW Stock  USD 90.28  1.13  1.24%   
Edwards Lifesciences financial statements provide useful quarterly and yearly information to potential Edwards Lifesciences Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Edwards Lifesciences financial statements helps investors assess Edwards Lifesciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Edwards Lifesciences' valuation are summarized below:
Gross Profit
4.3 B
Profit Margin
0.2336
Market Capitalization
54.3 B
Enterprise Value Revenue
8.8916
Revenue
B
There are over one hundred nineteen available fundamental signals for Edwards Lifesciences Corp, which can be analyzed over time and compared to other ratios. All traders should should verify Edwards Lifesciences' prevailing fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to climb to about 45.9 B in 2024. Enterprise Value is likely to climb to about 45.4 B in 2024

Edwards Lifesciences Total Revenue

6.31 Billion

Check Edwards Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edwards main balance sheet or income statement drivers, such as Depreciation And Amortization of 83.4 M, Interest Expense of 10.6 M or Selling General Administrative of 1.8 B, as well as many exotic indicators such as Price To Sales Ratio of 4.36, Dividend Yield of 0.0035 or PTB Ratio of 4.82. Edwards financial statements analysis is a perfect complement when working with Edwards Lifesciences Valuation or Volatility modules.
  
This module can also supplement Edwards Lifesciences' financial leverage analysis and stock options assessment as well as various Edwards Lifesciences Technical models . Check out the analysis of Edwards Lifesciences Correlation against competitors.

Edwards Lifesciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.8 B9.4 B5.4 B
Slightly volatile
Other Current Liabilities14.4 M15.2 M225.6 M
Slightly volatile
Total Current Liabilities1.3 B1.2 B747 M
Slightly volatile
Total Stockholder EquityB6.7 B3.5 B
Slightly volatile
Property Plant And Equipment Net1.9 B1.8 B943.4 M
Slightly volatile
Retained Earnings9.4 BBB
Slightly volatile
Non Current Assets Total5.6 B5.3 BB
Slightly volatile
Non Currrent Assets Other486.9 M463.7 M145.4 M
Slightly volatile
Cash And Short Term Investments1.7 B1.6 B1.1 B
Slightly volatile
Net Receivables878.7 M836.9 M501.1 M
Slightly volatile
Good Will688.6 M1.3 B829.5 M
Slightly volatile
Common Stock Shares Outstanding550.8 M609.4 M649.6 M
Slightly volatile
Liabilities And Stockholders Equity9.8 B9.4 B5.4 B
Slightly volatile
Non Current Liabilities Total800.7 M1.4 B1.1 B
Slightly volatile
Inventory1.2 B1.2 B577 M
Slightly volatile
Other Current Assets251.3 M239.3 M138.7 M
Slightly volatile
Total Liabilities1.4 B2.6 B1.8 B
Slightly volatile
Property Plant And Equipment Gross2.8 B2.7 B1.1 B
Slightly volatile
Total Current Assets4.2 BB2.4 B
Slightly volatile
Short and Long Term Debt Total486.4 M694.9 M596.5 M
Slightly volatile
Other Liabilities963.1 M917.2 M603.8 M
Slightly volatile
Accounts Payable139.5 M201.4 M130.7 M
Slightly volatile
Cash1.2 B1.1 B740.3 M
Slightly volatile
Other Assets945.6 M900.6 M400.6 M
Slightly volatile
Long Term Debt425.6 M597 M516.9 M
Slightly volatile
Common Stock Total Equity780.4 M743.2 M342.2 M
Slightly volatile
Intangible Assets449.8 M428.4 M273.5 M
Slightly volatile
Common Stock683 M650.5 M329.6 M
Slightly volatile
Property Plant Equipment2.1 BB948.1 M
Slightly volatile
Short Term Investments382.6 M500.5 M396 M
Pretty Stable
Net Tangible Assets5.3 BB2.5 B
Slightly volatile
Capital Surpluse1.2 B2.3 B1.2 B
Slightly volatile
Long Term Investments582.2 M583.9 M532.8 M
Slightly volatile
Non Current Liabilities Other454.3 M264.3 M415.8 M
Slightly volatile
Deferred Long Term Asset Charges246.1 M234.4 M157.4 M
Slightly volatile
Long Term Debt Total583.3 M685.7 M518.9 M
Slightly volatile
Short and Long Term Debt719.2 M687.7 M627 M
Pretty Stable
Cash And EquivalentsB884.4 M929.1 M
Very volatile
Net Invested Capital5.9 B7.2 B4.8 B
Slightly volatile
Net Working Capital2.2 B2.8 B1.6 B
Slightly volatile
Capital Stock551.6 M650.5 M352.1 M
Slightly volatile
Capital Lease Obligations103.8 M97.9 M89 M
Slightly volatile

Edwards Lifesciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization83.4 M144.9 M91.2 M
Slightly volatile
Selling General Administrative1.8 B1.8 B1.1 B
Slightly volatile
Total Revenue6.3 BB3.5 B
Slightly volatile
Gross Profit4.9 B4.6 B2.7 B
Slightly volatile
Other Operating Expenses4.5 B4.3 B2.6 B
Slightly volatile
Operating Income1.6 B1.5 B931.8 M
Slightly volatile
Research Development1.1 B1.1 B588.1 M
Slightly volatile
Cost Of Revenue697.9 M1.4 B828.6 M
Slightly volatile
Total Operating ExpensesB2.9 B1.7 B
Slightly volatile
Income Before Tax1.7 B1.6 B962.2 M
Slightly volatile
Net Income1.5 B1.4 B799.6 M
Slightly volatile
Income Tax Expense113.1 M198.7 M156.6 M
Pretty Stable
Net Income Applicable To Common Shares1.8 B1.8 B842.8 M
Slightly volatile
Net Income From Continuing Ops836.3 M1.4 B765.4 M
Slightly volatile
Tax Provision201.8 M207.6 M166 M
Pretty Stable
Interest Income70.6 M67.2 M21.5 M
Slightly volatile
Reconciled Depreciation121.6 M143.6 M97.9 M
Slightly volatile

Edwards Lifesciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow444.3 M629.5 M620.9 M
Slightly volatile
Depreciation81.8 M144.9 M88.7 M
Slightly volatile
Capital Expenditures146.6 M266.3 M193.2 M
Slightly volatile
Total Cash From Operating Activities590.9 M895.8 M814.1 M
Slightly volatile
Net Income1.5 B1.4 B796.6 M
Slightly volatile
End Period Cash Flow1.2 B1.1 B742.5 M
Slightly volatile
Stock Based Compensation146.4 M139.4 M79.3 M
Slightly volatile
Begin Period Cash Flow499 M772.6 M645.7 M
Slightly volatile
Cash Flows Other Operating1.8 B1.7 B859.4 M
Slightly volatile
Issuance Of Capital Stock169.1 M184.6 M154.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.367.7047.3373
Slightly volatile
Dividend Yield0.00350.00370.0292
Slightly volatile
PTB Ratio4.826.95657.6669
Slightly volatile
Days Sales Outstanding60.350.870754.4828
Slightly volatile
Book Value Per Share11.5110.96095.6341
Slightly volatile
Free Cash Flow Yield0.01290.01360.034
Slightly volatile
Invested Capital0.09930.10450.2475
Slightly volatile
Operating Cash Flow Per Share1.551.47651.3282
Slightly volatile
Stock Based Compensation To Revenue0.02930.02320.0279
Slightly volatile
PB Ratio4.826.95657.6669
Slightly volatile
EV To Sales4.397.62927.3115
Slightly volatile
Free Cash Flow Per Share1.091.03761.0074
Slightly volatile
ROIC0.120.18050.1719
Slightly volatile
Inventory Turnover1.121.18111.6988
Slightly volatile
Net Income Per Share2.432.31151.2761
Slightly volatile
Days Of Inventory On Hand324309226
Slightly volatile
Payables Turnover4.786.8516.9172
Pretty Stable
Sales General And Administrative To Revenue0.360.30370.3188
Slightly volatile
Research And Ddevelopement To Revenue0.10.17850.1515
Slightly volatile
Cash Per Share2.852.71061.812
Slightly volatile
POCF Ratio54.2251.64232.7218
Slightly volatile
Payout Ratio0.120.12110.7912
Slightly volatile
PFCF Ratio77.1673.488344.9109
Slightly volatile
Days Payables Outstanding95.1353.276660.4895
Very volatile
Income Quality0.610.64011.2115
Slightly volatile
ROE0.110.21090.2126
Very volatile
EV To Operating Cash Flow53.751.140632.5596
Slightly volatile
PE Ratio31.3432.986935.5028
Slightly volatile
Return On Tangible Assets0.0960.18260.1734
Very volatile
EV To Free Cash Flow76.4172.774944.6743
Slightly volatile
Earnings Yield0.01690.03030.0332
Slightly volatile
Intangibles To Total Assets0.320.17960.2337
Pretty Stable
Current Ratio2.333.3763.4179
Slightly volatile
Tangible Book Value Per Share8.728.30313.9686
Slightly volatile
Receivables Turnover5.457.17516.7605
Slightly volatile
Graham Number25.0723.876112.6476
Slightly volatile
Shareholders Equity Per Share11.5110.96095.6341
Slightly volatile
Debt To Equity0.09930.10450.2475
Slightly volatile
Revenue Per Share10.399.89755.628
Slightly volatile
Interest Debt Per Share1.231.17440.9828
Slightly volatile
Debt To Assets0.07050.07420.1384
Slightly volatile
Short Term Coverage Ratios22.0535.975921.2631
Slightly volatile
Price Earnings Ratio31.3432.986935.5028
Slightly volatile
Operating Cycle188360268
Slightly volatile
Price Book Value Ratio4.826.95657.6669
Slightly volatile
Days Of Payables Outstanding95.1353.276660.4895
Very volatile
Dividend Payout Ratio0.120.12110.7912
Slightly volatile
Price To Operating Cash Flows Ratio54.2251.64232.7218
Slightly volatile
Price To Free Cash Flows Ratio77.1673.488344.9109
Slightly volatile
Pretax Profit Margin0.140.26610.2524
Pretty Stable
Ebt Per Ebit0.621.04171.0551
Pretty Stable
Operating Profit Margin0.160.25550.2405
Slightly volatile
Effective Tax Rate0.220.12430.1939
Slightly volatile
Company Equity Multiplier1.821.4081.5808
Pretty Stable
Long Term Debt To Capitalization0.0870.09150.1684
Slightly volatile
Total Debt To Capitalization0.08990.09460.181
Slightly volatile
Return On Capital Employed0.140.18780.1888
Slightly volatile
Debt Equity Ratio0.09930.10450.2475
Slightly volatile
Ebit Per Revenue0.160.25550.2405
Slightly volatile
Quick Ratio1.512.07582.3385
Slightly volatile
Net Income Per E B T0.650.87750.7975
Pretty Stable
Cash Ratio0.680.9570.9843
Very volatile
Cash Conversion Cycle322307232
Slightly volatile
Operating Cash Flow Sales Ratio0.170.14920.2424
Very volatile
Days Of Inventory Outstanding324309226
Slightly volatile
Days Of Sales Outstanding60.350.870754.4828
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.580.70270.7414
Pretty Stable
Cash Flow Coverage Ratios1.11.28911.4071
Pretty Stable
Price To Book Ratio4.826.95657.6669
Slightly volatile
Fixed Asset Turnover4.913.25754.3712
Slightly volatile
Price Cash Flow Ratio54.2251.64232.7218
Slightly volatile
Debt Ratio0.07050.07420.1384
Slightly volatile
Cash Flow To Debt Ratio1.11.28911.4071
Pretty Stable
Price Sales Ratio4.367.7047.3373
Slightly volatile
Return On Assets0.0780.14980.1359
Pretty Stable
Asset Turnover0.80.64130.6865
Slightly volatile
Net Profit Margin0.250.23350.2116
Slightly volatile
Gross Profit Margin0.540.77020.7168
Pretty Stable
Price Fair Value4.826.95657.6669
Slightly volatile
Return On Equity0.110.21090.2126
Very volatile

Edwards Lifesciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap45.9 B43.7 B36.7 B
Slightly volatile
Enterprise Value45.4 B43.3 B36.4 B
Slightly volatile

Edwards Fundamental Market Drivers

Forward Price Earnings32.8947
Cash And Short Term Investments1.6 B

Edwards Upcoming Events

6th of February 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Edwards Lifesciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Edwards Lifesciences income statement, its balance sheet, and the statement of cash flows. Edwards Lifesciences investors use historical funamental indicators, such as Edwards Lifesciences's revenue or net income, to determine how well the company is positioned to perform in the future. Although Edwards Lifesciences investors may use each financial statement separately, they are all related. The changes in Edwards Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Edwards Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Edwards Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Edwards Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue953.9 M554.1 M
Total RevenueB6.3 B
Cost Of Revenue1.4 B697.9 M
Stock Based Compensation To Revenue 0.02  0.03 
Sales General And Administrative To Revenue 0.30  0.36 
Research And Ddevelopement To Revenue 0.18  0.10 
Capex To Revenue(0.04)(0.05)
Revenue Per Share 9.90  10.39 
Ebit Per Revenue 0.26  0.16 

Pair Trading with Edwards Lifesciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edwards Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edwards Lifesciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Edwards Stock

  0.71ENSG Ensign Group Financial Report 24th of April 2024 PairCorr

Moving against Edwards Stock

  0.84INNV InnovAge Holding Corp Financial Report 14th of May 2024 PairCorr
  0.83XRAY Dentsply Sirona Financial Report 1st of May 2024 PairCorr
  0.78LUCY Innovative EyewearPairCorr
  0.73MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr
  0.71ACHC Acadia Healthcare Financial Report 24th of April 2024 PairCorr
The ability to find closely correlated positions to Edwards Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edwards Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edwards Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edwards Lifesciences Corp to buy it.
The correlation of Edwards Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edwards Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edwards Lifesciences Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edwards Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Edwards Lifesciences Corp is a strong investment it is important to analyze Edwards Lifesciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Edwards Lifesciences' future performance. For an informed investment choice regarding Edwards Stock, refer to the following important reports:
Check out the analysis of Edwards Lifesciences Correlation against competitors.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Edwards Stock analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Commodity Directory
Find actively traded commodities issued by global exchanges
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.06)
Earnings Share
2.3
Revenue Per Share
9.897
Quarterly Revenue Growth
0.138
Return On Assets
0.1225
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.